Keith Douglas S, Vranic Gayle M
Division of Nephrology, University of Virginia, Charlottesville, Virginia
Division of Nephrology, University of Virginia, Charlottesville, Virginia.
Clin J Am Soc Nephrol. 2016 Apr 7;11(4):684-93. doi: 10.2215/CJN.05930615. Epub 2016 Feb 25.
For patients with ESRD, kidney transplant offers significant survival and quality-of-life advantages compared with dialysis. But for patients seeking transplant who are highly sensitized, wait times have traditionally been long and options limited. The approach to the highly sensitized candidate for kidney transplant has changed substantially over time owing to new advances in desensitization, options for paired donor exchange (PDE), and changes to the deceased-donor allocation system. Initial evaluation should focus on determining living-donor availability because a compatible living donor is always the best option. However, for most highly sensitized candidates this scenario is unlikely. For candidates with an incompatible donor, PDE can improve the prospects of finding a compatible living donor but for many highly sensitized patients the probability of finding a match in the relatively small pools of donors in PDE programs is limited. Desensitization of a living donor/recipient pair with low levels of incompatibility is another reasonable approach. But for pairs with high levels of pathologic HLA antibodies, outcomes after desensitization for the patient and allograft are less optimal. Determining the degree of sensitization by calculated panel-reactive antibody (cPRA) is critical in counseling the highly sensitized patient on expected wait times to deceased-donor transplant. For candidates with a high likelihood of finding a compatible deceased donor in a reasonable time frame, waiting for a kidney is a good strategy. For the candidate without a living donor and with a low probability of finding a deceased-donor match, desensitization on the waiting list can be considered. The approach to the highly sensitized kidney transplant candidate must be individualized and requires careful discussion among the transplant center, patient, and referring nephrologist.
对于终末期肾病(ESRD)患者,与透析相比,肾移植在生存率和生活质量方面具有显著优势。但对于高度致敏的寻求移植的患者,传统上等待时间很长且选择有限。由于脱敏技术的新进展、配对供体交换(PDE)的选择以及 deceased-donor 分配系统的变化,针对高度致敏的肾移植候选者的方法随着时间的推移发生了很大变化。初始评估应侧重于确定活体供体的可用性,因为相容的活体供体始终是最佳选择。然而,对于大多数高度致敏的候选者来说,这种情况不太可能。对于供体不相容的候选者,PDE 可以改善找到相容活体供体的前景,但对于许多高度致敏的患者来说,在 PDE 项目中相对较小的供体库中找到匹配的可能性有限。对不相容程度较低的活体供体/受者对进行脱敏是另一种合理的方法。但对于具有高水平病理性 HLA 抗体的配对,患者和同种异体移植物脱敏后的结果不太理想。通过计算群体反应性抗体(cPRA)来确定致敏程度对于向高度致敏患者咨询 deceased-donor 移植的预期等待时间至关重要。对于在合理时间框架内很有可能找到相容 deceased 供体的候选者,等待肾脏是一个好策略。对于没有活体供体且找到 deceased-donor 匹配可能性低的候选者,可以考虑在等待名单上进行脱敏。对于高度致敏的肾移植候选者的处理方法必须个体化,并且需要移植中心、患者和转诊肾病专家之间进行仔细讨论。